UNSPSC 51124303: Quinidine bisulfate

This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K043Q65TR, chemically known as 8alpha,9r-6-methoxycinchonan-9-ol, sulfate (1:1) salt but more generally known as quinidine bisulfate, which bears US NIH Compound Identifier 11069. European Medicines Agency schedules Quinidine bisulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15078MIG.

Most nations, for tariff and trade purposes, schedule quinidine bisulfate under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE BISULFATE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.OS(=O)(=O)O.

UNSPSC 51124303 Quinidine bisulfate is a Commodity code that encompasses individual pharmaceutical products procured by state and local health systems, emergency medical services, and multistate cooperative purchasing alliances. State and local buyers under this code solicit specific medications—named by National Drug Code (NDC), strength, dosage form, and unit quantity—for use in clinical settings, emergency response, and institutional pharmacy programs. The issuing bodies include municipal fire and rescue departments (such as Tampa Fire Rescue), state health agencies and their pharmacy benefit programs (such as the Texas Health and Human Services Commission), and multistate cooperative purchasing consortia (such as the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) that aggregate demand across participating state and local members. Procurement vehicles range from sealed-bid invitations for immediate supply needs to Request for Proposal (RFP) processes for longer-term framework agreements with multiple authorized distributors.

Recent activity spans Florida, Texas, and Minnesota, with MMCAP's cooperative structure extending reach to Oregon and other participating jurisdictions. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, soliciting Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the award carries a one-year base term with two optional one-year renewals and unilateral extension rights for up to three additional 30-day periods. The Minnesota Department of Administration issued RFP S1070000015802 via MMCAP on January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with contract effectiveness July 1, 2026 and a two-year base term. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities—an exploratory phase preceding formal competitive solicitation. MMCAP awards are multi-award capable and evaluated 75 percent on price competitiveness, with vendors required to maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act (DSCSA) standards.